Dong-Yan Shen

Prof. Dong-Yan Shen

Biobank, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
GHGui-Li Huang
Gui-Li Huang
QLQi Luo
Qi Luo
GRGang Rui
Gang Rui
WZWei Zhang
Wei Zhang
QZQiu-Yan Zhang
Qiu-Yan Zhang
DSDong-Yan Shen
Dong-Yan Shen
Aberrant expression and function of retinoic acid receptor γ (RARγ) are often involved in the progression of several cancers. However, the role of RARγ in cholangiocarcinoma (CCA), chemoresistant bile duct carcinoma with a poor prognosis, remains unclear. In the present study, we found that RARγ was frequently overexpressed in human CCA specimens. Its overexpression was associated with poor differentiation, lymph node metastasis, high serum carbohydrate antigen 19-9 level, and poor prognosis of CCA. Downregulation of RARγ reduced CCA cell proliferation, migration, invasion, and colony formation ability in vitro and tumorigenic potential in nude mice. RARγ knockdown resulted in upregulation of cell cycle inhibitor P21, as well as downregulation of cyclin D1, proliferating cell nuclear antigen, and matrix metallopeptidase 9, in parallel with suppression of the Akt/NF-κB pathway. Furthermore, overexpression of RARγ contributed to the multidrug chemoresistance of CCA cells, at least in part due to upregulation of P glycoprotein via activation of the Wnt/β-catenin pathway. Molecular mechanism studies revealed that RARγ interacted with β-catenin and led to β-catenin nuclear translocation. Taken together, our results suggested that RARγ plays an important role in the proliferation, metastasis, and chemoresistance of CCA through simultaneous activation of the Akt/NF-κB and Wnt/β-catenin pathways, serving as a potential molecular target for CCA treatment.

10 March 2017 in Cell Cycle
Verified
Journal Article
Closed access
GHGui-Li Huang
Gui-Li Huang
WSWei Song
Wei Song
PZPan Zhou
Pan Zhou
QFQi-Rui Fu
Qi-Rui Fu
CLChen-Lu Lin
Chen-Lu Lin
DSDong-Yan Shen
Dong-Yan Shen
Retinoic acid receptor γ (RARγ), a unique member of the nuclear receptor superfamily, plays an important role in the progression of several cancers such as hepatocellular carcinoma, esophageal cancer, and cholangiocarcinoma. However, little is known about the regulatory mechanism of the RARγ expression in colorectal cancer (CRC) progression. In the present study, we found that RARγ was frequently overexpressed in human CRC specimens and CRC cell lines, and it mainly resided in the cytoplasm in CRC specimens. Tissue microarrays showed that RARγ indicated vital clinical significance in CRC. RARγ knockdown neither affected CRC cell proliferation nor blocked the cell cycle of CRC cells. However, RARγ knockdown increased the sensitivity of CRC cells to chemotherapeutics through downregulation of multi-drug resistance 1(MDR1). Further studies suggested that RARγ knockdown resulted in downregulation of MDR1, in parallel with suppression of the Wnt/β-catenin pathway. Moreover, a significantly positive association between RARγ and MDR1 was demonstrated in CRC tissue microarrays. Collectively, these results suggested that overexpression of RARγ contributed to the multidrug chemoresistance of CRC cells, at least in part due to upregulation of MDR1 via activation of the Wnt/β-catenin pathway, indicating that RARγ might serve as a potential therapeutic target for chemoresistant CRC patients.

28 May 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
YFYanyun Fan
Yanyun Fan
YSYing Shi
Ying Shi
ZLZhenhe Lin
Zhenhe Lin
XHXiaoxiao Huang
Xiaoxiao Huang
JLJinying Li
Jinying Li
WLWenming Liu
Wenming Liu

1 October 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SLSi-Yang Li
Si-Yang Li
JSJin Shang
Jin Shang
XMXiao-Mei Mao
Xiao-Mei Mao
RFRui Fan
Rui Fan
HLHui-Qi Li
Hui-Qi Li
DSDong-Yan Shen
Dong-Yan Shen

1 October 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
FZFu-Hui Zhang
Fu-Hui Zhang
HRHong-Yue Ren
Hong-Yue Ren
JSJin-Xing Shen
Jin-Xing Shen
XZXiao-Yun Zhang
Xiao-Yun Zhang
HYHuiming Ye
Huiming Ye
DSDong-Yan Shen
Dong-Yan Shen

20 February 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HYHong-Yi Yang
Hong-Yi Yang
JSJin-Xing Shen
Jin-Xing Shen
YWYi Wang
Yi Wang
YLYu Liu
Yu Liu
DSDong-Yan Shen
Dong-Yan Shen
SQSong Quan
Song Quan
Tankyrase (TNKS) plays important roles in the malignancy of several cancers such as human lung tumor, breast cancer, and hepatocellular cancer. However, its exact functions and molecular mechanisms in ovarian cancer remain unclear. In this study, we found that TNKS was aberrantly overexpressed in human ovarian cancer tissues and associated with poor patient prognosis. TNKS inhibition or knockdown not only reduced ovarian cancer cell proliferation, colony formation, migration, invasion, and tumorigenic potential in nude mice but also enhanced the drug susceptibility of ovarian cancer cells through arresting cell cycle and inducing apoptosis. These phenotypic changes correlated with downregulation of targets (Cyclin D1, MDR, and MMP-9) of Wnt/β-catenin signaling. Furthermore, downregulation of TNKS suppressed the glucose uptake, lactate excretion, and cellular ATP levels and increased cellular O2consumption rates. Molecular mechanism studies revealed that TNKS promoted aerobic glycolysis at least in part due to upregulation of pyruvate carboxylase (PC) via activation of Wnt/β-catenin/snail signaling. In agreement with these findings, expression of TNKS is positively associated with snail and PC in clinical ovarian cancer samples. Our findings identified TNKS as an oncogenic regulator of ovarian cancer cells proliferation that promotes aerobic glycolysis via activation of Wnt/β-catenin signaling, indicating that the TNKS might serve as a potential molecular target for clinical therapy of Wnt/β-catenin dependent ovarian cancer.